Table 2.
Adjusted estimates of the HR of cSVD phenotypes for outcome events.
| cSVD phenotypes | HR (95% CI)† | P | HR (95% CI)* | P |
|---|---|---|---|---|
| Ischemic stroke | Hemorrhagic stroke | |||
| Mild-moderate WMH | 1 [Reference] | 1 [Reference] | ||
| Advanced WMH | 1.37 (0.69–2.72) | 0.371 | 1.36 (0.36–5.21) | 0.651 |
| ICH with mild-moderate WMH | 1.16 (0.61–2.23) | 0.649 | 1.07 (0.32–3.59) | 0.918 |
| ICH with advanced WMH | 2.62 (1.22–5.60) | 0.013 | 3.75 (0.85–16.53) | 0.080 |
| Stroke, MI, or vascular death | All-cause death | |||
|---|---|---|---|---|
| Mild-moderate WMH | 1 [Reference] | 1 [Reference] | ||
| Advanced WMH | 1.20 (0.67–2.15) | 0.545 | 1.45 (0.52–4.07) | 0.478 |
| ICH with mild-moderate WMH | 1.04 (0.61–1.79) | 0.885 | 1.76 (0.68–4.55) | 0.242 |
| ICH with advanced WMH | 2.63 (1.40–4.95) | 0.003 | 2.86 (0.91–8.94) | 0.071 |
cSVD cerebral small-vessel disease, WMH white mater hyperintensity, MI myocardial infarction, HR hazard ratio, CI confidence interval.
*Adjusted for age, sex, smoking, qualifying stroke severity, presence of lacune, presence of CMB, heart rate, mini-mental state examination, glycosylated hemoglobin, triglycerides, uric acid, statin use, antihypertensive use, probucol use, and cilostazol use.